News

BioMed SA eyes new road map to greater economic wins

BioMed SA President Ann Stevens (Photo by Lyndsey Johnson) By W. Scott Bailey, San Antonio Business ...

Military champion has Prytime Medical ready for prime time

Prytime Medical Devices Inc. CEO David Spencer said his company is poised to take its flagship technology ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...

News
LifeCell Corp. acquires new fat-injection technology from California medical device incubator
January 27, 2014

LifeCell Corp., a sister company to Kinetic Concepts Inc., has purchased a fat-grafting technology from adipose Tissue Injector that will allow it to expand further into the reconstructive and cosmetic procedures market.

By W. Scott Bailey, San Antonio Business Journal

Officials with San Antonio-based Kinetic Concepts Inc. (KCI) say sister company LifeCell Corp. has acquired an advanced adipose Tissue Injector, or aTI, from TauTona Group, a medical device incubator based in Menlo Park, Calif.

The acquisition gives LifeCell access to fat-grafting technology that will allow the company to expand its work in the reconstructive and cosmetic procedures arena.

I reported last year that KCI had struck a deal to bring LifeCell and Systagenix under one roof, creating a globally diversified company that is based in San Antonio and focused on wound care, biologics and regenerative medicine.

"With this acquisition (of the aTI), we will leverage the LifeCell sales channel in the reconstructive and plastic surgery fields to commercialize this exciting new technology," says KCI President and CEO Joe Woody. "We continue to be focused on innovation and acquisitions of technologies and platforms that both complement and further diversify our combined product portfolio."

The aTI is a battery-powered, single-use tool which manages the pressure and flow rates during injection, minimizing damage to the injected fat.

"The acquisition of the adipose Tissue Injector demonstrates our ongoing commitment to providing clinicians with the tools they need to provide efficient, cost-effective surgical and reconstructive procedures to their patients," says LifeCell Senior Vice President Philip Croxford.

 

Stay informed. Subscribe to BioMed SA news alerts.